Neil Stahl - Feb 2, 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Research and Development
Signature
/s/**Neil Stahl
Stock symbol
REGN
Transactions as of
Feb 2, 2024
Transactions value $
-$9,438,846
Form type
4
Date filed
2/6/2024, 04:08 PM
Previous filing
Dec 12, 2023
Next filing
Feb 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $12.3M +30.8K +59.11% $399.66 82.8K Feb 2, 2024 Direct
transaction REGN Common Stock Tax liability -$21.7M -22.7K -27.44% $956.65 60.1K Feb 2, 2024 Direct
holding REGN Common Stock 5.83K Feb 2, 2024 By 401(k) Plan
holding REGN Common Stock 4.61K Feb 2, 2024 by Spouse as Trustee

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -30.8K -100% $0.00* 0 Feb 2, 2024 Common Stock 30.8K $399.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.